146 related articles for article (PubMed ID: 24193859)
1. [Home-based infusion therapy--a feasible approach for chronically ill patients? A new path to provide superior patient care exemplified for Fabry's disease].
Beck M; Gaedeke J; Martus P; Karabul N; Rolfs A
Dtsch Med Wochenschr; 2013 Nov; 138(46):2345-50. PubMed ID: 24193859
[TBL] [Abstract][Full Text] [Related]
2. Home infusion program for Fabry disease: experience with agalsidase alfa in Argentina.
Kisinovsky I; Cáceres G; Coronel C; Reisin R
Medicina (B Aires); 2013; 73(1):31-4. PubMed ID: 23335703
[TBL] [Abstract][Full Text] [Related]
3. Intravenous enzyme replacement therapy: better in home or hospital?
Milligan A; Hughes D; Goodwin S; Richfield L; Mehta A
Br J Nurs; 2006 Mar 23-Apr 12; 15(6):330-3. PubMed ID: 16628169
[TBL] [Abstract][Full Text] [Related]
4. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.
Schiffmann R; Ries M; Timmons M; Flaherty JT; Brady RO
Nephrol Dial Transplant; 2006 Feb; 21(2):345-54. PubMed ID: 16204287
[TBL] [Abstract][Full Text] [Related]
5. Decline of plasma brain natriuretic peptide during enzyme replacement therapy in a female patient with heterozygous Fabry's disease.
Masugata H; Senda S; Goda F; Yamagami A; Okuyama H; Kohno T; Hosomi N; Yukiiri K; Noma T; Murao K; Kohno M; Itoh S
Tohoku J Exp Med; 2009 Mar; 217(3):169-74. PubMed ID: 19282651
[TBL] [Abstract][Full Text] [Related]
6. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease.
Ramaswami U; Wendt S; Pintos-Morell G; Parini R; Whybra C; Leon Leal JA; Santus F; Beck M
Acta Paediatr; 2007 Jan; 96(1):122-7. PubMed ID: 17187618
[TBL] [Abstract][Full Text] [Related]
8. A revised home treatment algorithm for Fabry disease: influence of antibody formation.
Smid BE; Hoogendijk SL; Wijburg FA; Hollak CE; Linthorst GE
Mol Genet Metab; 2013 Feb; 108(2):132-7. PubMed ID: 23332169
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.
Mehta A; Beck M; Elliott P; Giugliani R; Linhart A; Sunder-Plassmann G; Schiffmann R; Barbey F; Ries M; Clarke JT;
Lancet; 2009 Dec; 374(9706):1986-96. PubMed ID: 19959221
[TBL] [Abstract][Full Text] [Related]
10. Home treatment for Fabry disease: practice guidelines based on 3 years experience in The Netherlands.
Linthorst GE; Vedder AC; Ormel EE; Aerts JM; Hollak CE
Nephrol Dial Transplant; 2006 Feb; 21(2):355-60. PubMed ID: 16249196
[TBL] [Abstract][Full Text] [Related]
11. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
Thofehrn S; Netto C; Cecchin C; Burin M; Matte U; Brustolin S; Nunes AC; Coelho J; Tsao M; Jardim L; Giugliani R; Barros EJ
Ren Fail; 2009; 31(9):773-8. PubMed ID: 19925283
[TBL] [Abstract][Full Text] [Related]
12. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.
Schiffmann R; Pastores GM; Lien YH; Castaneda V; Chang P; Martin R; Wijatyk A
Orphanet J Rare Dis; 2014 Nov; 9():169. PubMed ID: 25425121
[TBL] [Abstract][Full Text] [Related]
13. Enzyme replacement therapy in Fabry's disease: recent advances and clinical applications.
Mignani R; Cagnoli L
J Nephrol; 2004; 17(3):354-63. PubMed ID: 15365954
[TBL] [Abstract][Full Text] [Related]
14. Right ventricular involvement in patients with Fabry's disease and the effect of enzyme replacement therapy.
Wuest W; Machann W; Breunig F; Weidemann F; Koestler H; Hahn D; Wanner C; Beer M
Rofo; 2011 Nov; 183(11):1037-42. PubMed ID: 21959886
[TBL] [Abstract][Full Text] [Related]
15. Deceased renal transplantation in patient with Fabry's disease maintained by enzyme replacement therapy.
Kato T; Nishimura K; Ichikawa Y
Int J Urol; 2009 Jul; 16(7):650. PubMed ID: 19659805
[No Abstract] [Full Text] [Related]
16. Home-based infusion therapy for patients with Fabry disease.
Cousins A; Lee P; Rorman D; Raas-Rothschild A; Banikazemi M; Waldek S; Thompson L
Br J Nurs; 2008 May 22-Jun 11; 17(10):653-7. PubMed ID: 18563007
[TBL] [Abstract][Full Text] [Related]
17. [Intravenous enzyme substitution therapy in children with Fabry's disease].
Tøndel C; Laegreid LM; Hirth A; Houge G; Månsson JE; Søvik O
Tidsskr Nor Laegeforen; 2003 Dec; 123(23):3388-90. PubMed ID: 14713976
[TBL] [Abstract][Full Text] [Related]
18. [Fabry disease: demographic data since introduction of enzyme replacement therapy].
Cybulla M; Walter K; Neumann HP; Widmer U; Schärer M; Sunder-Plassmann G; Jansen T; Rolfs A; Beck M
Dtsch Med Wochenschr; 2007 Jul; 132(28-29):1505-9. PubMed ID: 17607649
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of replacement enzyme therapy on central nervous system manifestations in Fabry's disease].
Besson G; Vadot W; Guellerin J
Rev Med Interne; 2010 Dec; 31 Suppl 2():S257-9. PubMed ID: 21211675
[TBL] [Abstract][Full Text] [Related]
20. Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol.
Riccio E; Zanfardino M; Franzese M; Capuano I; Buonanno P; Ferreri L; Amicone M; Pisani A
Mol Genet Genomic Med; 2021 May; 9(5):e1659. PubMed ID: 33755336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
